UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Conditions:Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Blood Cancer, Lymphoma, Hematology, Hematology, Hematology, Hematology, Hematology, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Age Range:Any - 75
Start Date:May 15, 2017
End Date:December 2029
Contact:Timothy Krepski

Use our guide to learn which trials are right for you!

Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body
irradiation (TBI) preparative regimen with modifications based on factors including
diagnosis, disease status, and prior treatment. Single or double unit selected according to
current University of Minnesota umbilical cord blood graft selection algorithm.

Inclusion Criteria:

- Age, Performance Status, and Graft Criteria

- <70 years of age with no matched 5/6 or 6/6 sibling donor - patients ≥ 70 and ≤
75 years of age may be eligible if they have a Co-Morbidity score ≤ 2

- Karnofsky score ≥ 70% (≥ 16 years) or Lansky score ≥ 50 (< 16 years)

- UCB graft selected according to current University of Minnesota umbilical cord
blood graft selection algorithm

- Eligible Diseases All diseases listed below are advanced hematologic malignancies not
curable by conventional chemotherapy. Responses to conventional treatment range from
zero to 30% but are typically short lived.

- Acute Leukemias: Must be in remission by morphology (<5% blasts). Note
cytogenetic relapse or persistent disease without morphologic relapse is
acceptable. Also a small percentage of blasts that is equivocal between marrow
regeneration vs. early relapse are acceptable provided there are no associated
cytogenetic markers consistent with relapse.

- Acute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater
complete remission (CR); first complete remission (CR1) in patients > 60
years old; CR1 in ≤ 60 years old that is NOT considered as favorable-risk.
Favorable risk AML is defined as having one of the following:

- t(8,21) without cKIT mutation

- inv(16) or t(16;16) without cKIT mutation

- Normal karyotype with mutated NPM1 and wild type FLT-ITD

- Normal karyotype with double mutated CEBPA

- Acute prolymphocytic leukemia (APL) in first molecular remission at the
end of consolidation

- Acute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1
unable to tolerate consolidation chemotherapy due to chemotherapy-related
toxicities; CR1 high-risk ALL. High risk ALL is defined as having one of the

- Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11),
other MLL rearrangements, IKZF1

- 30 years of age or older at diagnosis

- White blood cell counts of greater than 30,000/mcL (B-ALL) or greater
than 100,000/mcL (T-ALL) at diagnosis

- CNS leukemia involvement during the course of disease

- Slow cytologic response (>10% lymphoblasts in bone marrow on Day 14 of
induction therapy)

- Evidence of persistent immonophenotypic or molecular minimal residual
disease (MRD) at the end of induction and consolidation therapy

- Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR

- Chronic myelogenous leukemia in chronic or accelerated phase, or CML blast crisis
in morphological remission (<5% blasts): Chronic phase patients must have failed
at least two tyrosine kinase inhibitors, been intolerant to all available TKIs,
or have T315I mutation.

- Myelodysplastic syndrome: IPSS INT-2 or High Risk; R-IPSS High or Very High; WHO
classification: RAEB-1, RAEB-2; Severe Cytopenias: ANC < 0.8, Anemia or
thrombocytopenia requiring transfusion; Poor or very poor risk cytogenetics based
on IPSS or R-IPSS definitions; therapy-related MDS. Blasts must be < 5% by bone
marrow aspirate morphology. If ≥5% blasts, patient requires chemotherapy for
cytoreduction to <5% blasts prior to transplantation.

- MRD positive leukemia (AML, ALL or accelerated/blast phase CML). Selected
patients in morphologic CR, but with positive immunophenotypic (flow cytometry)
or molecular evidence of MRD may be eligible if recent chemotherapy has not
resulted in MRD negative status.

- Leukemia or MDS in aplasia. These patients may be taken to transplant if after
induction therapy they remain with aplastic bone marrow and no morphological or
flow-cytometry evidence of disease ≥ 28 days post-therapy. These high risk
patients will be analyzed separately.

- Burkitt's lymphoma in CR2 or subsequent CR

- Relapsed T-Cell Lymphoma that is chemotherapy sensitive in CR/PR that has failed
or ineligible for an autologous transplant.

- Natural killer cell malignancies

- Large-cell lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy
sensitive disease who are ineligible for an autologous transplant.

- Relapsed Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),
marginal zone B-cell lymphoma, follicular lymphoma which have progressed within
12 months of achieving a partial or complete remission. Patients who had
remissions lasting > 12 months, are eligible after at least two prior therapies.
Patients with bulky disease should be considered for debulking chemotherapy
before transplant. Patients with refractory disease are eligible, unless bulky
disease and an estimated tumor doubling time of less than one month.

- Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are
eligible after initial therapy if chemotherapy sensitive.

- Relapsed Multiple Myeloma that is chemotherapy sensitive and has failed or
ineligible for an autologous transplant.

- Plasma Cell Leukemia after initial therapy if achieved at least in partial
remission; or relapsed and achieved subsequent remission (CR/PR)

- Acquired Bone marrow failure syndromes, except for Fanconi anemia

- Myeloproliferative Neoplasms/Myelofibrosis

- Other Leukemia Subtypes: A major effort in the field of hematology is to identify
patients who are of high risk for treatment failure so that patients can be
appropriately stratified to either more (or less) intensive therapy. This effort
is continually ongoing and retrospective studies identify new disease features or
characteristics that are associated with treatment outcomes. Therefore, if new
features are identified after the writing of this protocol, patients can be
enrolled with the approval of two members of the study committee.

- Additional Criteria for Bulky Disease (lymphomas)

- If stable disease is best response, the largest residual nodal mass must < 5 cm

- If response to previous therapy, the largest residual mass must represent a 50%
reduction and be < 7.5 cm (approximately)

- Organ Function Criteria

Adequate organ function is defined as:

- Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia
and left ventricular ejection fraction > 40%. For children that are not able to
cooperate with MUGA and echocardiography, such should be clearly stated in the
physician's note.

- Pulmonary: DLCO, FEV1, FVC ≥ 40% predicted, and absence of O2 requirements. For
children that are not able to cooperate with PFTs, a pulse oximetry with exercise
should be attempted. If neither test can be obtained it should be clearly stated in
the physician's note.

- Liver: Transaminases ≤ 5 x upper limit of normal (ULN) and total bilirubin ≤ 2.5 mg/dL
except for patients with Gilbert's syndrome or hemolysis

- Renal: Creatinine ≤ 2.0 mg/dl (adults) and creatinine clearance ≥ 40 mL/min
(pediatrics). Adults with a creatinine > 1.2 mg/dl or a history of renal dysfunction
must have estimated creatinine clearance ≥ 40 ml/min/1.73m^2. Adequate performance
status is defined as Karnofsky score ≥ 70% (≥ 16 years of age) or Lansky score ≥ 50

- Sexually active females of childbearing potential and males with partners of
child-bearing potential must agree to use adequate birth control during study

- Voluntary written consent (adult or parent/guardian with presentation of the
minor information sheet, if appropriate)

Exclusion Criteria:

- Pregnant or breast feeding. The agents used in this study include Pregnancy Category
D: known to cause harm to a fetus. Females of childbearing potential must have a
negative pregnancy test prior to starting therapy.

- Untreated active infection

- Active HIV infection or known HIV positive serology

- Less than 3 months since prior myeloablative transplant

- Evidence of progressive disease by imaging modalities or biopsy - persistent PET
activity, though possibly related to lymphoma, is not an exclusion criterion in the
absence of CT changes indicating progression.

- CML in blast crisis

- Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on
salvage therapy.

- Active central nervous system malignancy
We found this trial at
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
Phone: 612-625-3918
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
Minneapolis, MN
Click here to add this to my saved trials